Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01827163 · ClinicalTrials.gov registry record · Phase 2
Paclitaxel With Trastuzumab and Lapatinib in HER2-Positive Early Stage Breast Cancer
A Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
NCT01827163: Completed Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT01827163 is a Phase 2 study that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 20 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01827163, a Phase 2 study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
Study Summary
The purpose of this study is to study a new treatment for HER2-positive breast cancer.
Interventions
- DRUG Trastuzumab
- DRUG Paclitaxel
- DRUG Pegfilgrastim
- DRUG Lapatinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2013-04 |
| Est. Completion | 2019-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01827163
The ClinicalTrials.gov registry entry for NCT01827163 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Trastuzumab is the first listed.
NCT01827163 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01827163 about?
NCT01827163 is a clinical study titled "Paclitaxel With Trastuzumab and Lapatinib in HER2-Positive Early Stage Breast Cancer". The purpose of this study is to study a new treatment for HER2-positive breast cancer.
What is the current status of trial NCT01827163?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2013-04. Estimated completion is 2019-01.
What interventions are being tested in trial NCT01827163?
The interventions under investigation include: Trastuzumab (DRUG), Paclitaxel (DRUG), Pegfilgrastim (DRUG), Lapatinib (DRUG).
Who is sponsoring clinical trial NCT01827163?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.